Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor

European Journal of Pharmaceutical Sciences

Volumn 56, Issue 1, 2014, Pages 113-119

  Denti, Paolo ^a   Sharp, Sarah Kate ^a   Kröger, Wendy L ^a   Schwager, Sylva L ^a   Mahajan, Aman ^a   Njoroge, Mathew ^a   Gibhard, Liezl ^a   Smit, Ian ^a   Chibale, Kelly ^a   Wiesner, Lubbe ^a   Sturrock, Edward D ^a   Davies, Neil H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Hypertension; LC MS MS method; Lisinopril tryptophan; Pharmacokinetic analysis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL TRYPTOPHAN; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; DIPEPTIDYL CARBOXYPEPTIDASE; LISINOPRIL; TRYPTOPHAN;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; ENZYME ACTIVE SITE; EX VIVO STUDY; IC 50; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; TANDEM MASS SPECTROMETRY; WISTAR RAT; ANIMAL; CACO 2 CELL LINE; CHEMISTRY; HUMAN; METABOLISM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CACO-2 CELLS; CATALYTIC DOMAIN; HUMANS; LISINOPRIL; MALE; PEPTIDYL-DIPEPTIDASE A; RATS, WISTAR; TRYPTOPHAN;

EID: 84897008574     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.01.012     Document Type: Article

References (42)

1. Acharya, K.R., Sturrock, E.D., Riordan, J.F., Ehlers, M.R., 2003. Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. 2, 891-902. (Pubitemid 37407795)
2. Adam, A., Cugno, M., Molinaro, G., Perez, M., Lepage, Y., Agostoni, A., 2002. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 359, 2088-2089. (Pubitemid 34680976)
3. Anderson, B.J., Holford, N.H., 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332. (Pubitemid 351738156)
4. Araujo, M.C., Melo, R.L., Cesari, M.H., Juliano, M.A., Juliano, L., Carmona, A.K., 2000. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 39, 8519-8525. (Pubitemid 30489949)
5. Beal, S., Sheiner, L., Boeckmann, A., and Bauer, R., 2009. NONMEM User's Guides (1989-2009) Icon Development Solutions, Ellicott City, MD, USA.
6. Beal, S.L., 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinetics Pharmacodynamics 28, 481-504. (Pubitemid 33151426)
7. Beal, S.L., Sheiner, L.B., 1982. Estimating population kinetics. Crit. Rev. Biomed. Eng. 8, 195-222.
8. Bernstein, K.E., Shen, X.Z., Gonzalez-Villalobos, R.A., Billet, S., Okwan-Duodu, D., Ong, F.S., Fuchs, S., 2011. Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr. Opin. Pharmacol. 11, 105-111.
9. Carmona, A.K., Schwager, S.L., Juliano, M.A., Juliano, L., Sturrock, E.D., 2006. A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay. Nat. Protoc. 1, 1971-1976. (Pubitemid 46773320)
10. Corradi, H.R., Chitapi, I., Sewell, B.T., Georgiadis, D., Dive, V., Sturrock, E.D., Acharya, K.R., 2007. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 46, 5473-5478. (Pubitemid 46717270)
11. Csajka, C., Verotta, D., 2006. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J. Pharmacokinetics Pharmacodynamics 33 (3), 227-279. (Pubitemid 44020382)
12. Cruciani, G., Pastor, M., Guba, W., 2000. Volsurf:a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. Suppl. 2, S29-S39.
13. Dagenais, G.R., Pogue, J., Fox, K., Simoons, M.L., Yusuf, S., 2006. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368, 581-588. (Pubitemid 44209181)
14. Davidian, M., Giltinan, D.M., 2003. Nonlinear models for repeated measurement data: an overview and update. J. Agric. Biol. Environ. Statist. 8 (4), 387-419. (Pubitemid 39364406)
15. Dive, V., Cotton, J., Yiotakis, A., Michaud, A., Vassiliou, S., Jiracek, J., Vazeux, G., Chauvet, M.T., Cuniasse, P., Corvol, P., 1999. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. U.S.A. 96, 4330-4335. (Pubitemid 29190336)
16. Ehlers, M.R., 2006. Safety issues associated with the use of angiotensin-converting enzyme inhibitors. Expert Opin. Drug Saf. 5, 739-740. (Pubitemid 44669486)
17. Emanueli, C., Grady, E.F., Madeddu, P., Figini, M., Bunnett, N.W., Parisi, D., Regoli, D., Geppetti, P., 1998. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 31, 1299-1304. (Pubitemid 28248831)
18. Fuchs, S., Xiao, H.D., Cole, J.M., Adams, J.W., Frenzel, K., Michaud, A., Zhao, H., Keshelava, G., Capecchi, M.R., Corvol, P., Bernstein, K.E., 2004. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J. Biol. Chem. 279, 15946-15953. (Pubitemid 38509282)
19. Fuchs, S., Xiao, H.D., Hubert, C., Michaud, A., Campbell, D.J., Adams, J.W., Capecchi, M.R., Corvol, P., Bernstein, K.E., 2008. Angiotensin-converting enzyme Cterminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267-274. (Pubitemid 351159938)
20. Georgiadis, D., Beau, F., Czarny, B., Cotton, J., Yiotakis, A., Dive, V., 2003. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ. Res. 93, 148-154. (Pubitemid 36919702)
21. Gordon, K., Redelinghuys, P., Schwager, S.L., Ehlers, M.R., Papageorgiou, A.C., Natesh, R., Acharya, K.R., Sturrock, E.D., 2003. Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. Biochem. J. 371, 437-442. (Pubitemid 36547627)
22. Holford, N.H.G., 2005. The visual predictive check superiority to standard diagnostic (Rorschach) plots.
23. Jonsson, E.N., Karlsson, M.O., 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Program Biomed. 58, 51-64. (Pubitemid 29049052)
24. Jullien, N.D., Cuniasse, P., Georgiadis, D., Yiotakis, A., Dive, V., 2006. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme. FEBS J. 273, 1772-1781. (Pubitemid 43779829)
25. Keizer, R.J., van, B.M., Beijnen, J.H., Schellens, J.H., Huitema, A.D., 2011. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput. Methods Program Biomed. 101, 72-79.
26. Kerns, E.H., Di, L., 2008. Drug-like properties: Concepts, structure design and methods - from ADME to toxicity optimization, first ed. Academic press/Elsevier.
27. Lindbom, L., Ribbing, J., Jonsson, E.N., 2004. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput. Methods Program Biomed. 75, 85-94. (Pubitemid 38798039)
28. Makani, H., Messerli, F.H., Romero, J., Wever-Pinzon, O., Korniyenko, A., Berrios, R.S., Bangalore, S., 2012. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am. J. Cardiol. 110, 383-391.
29. Matchar, D.B., McCrory, D.C., Orlando, L.A., Patel, M.R., Patel, U.D., Patwardhan, M.B., Powers, B., Samsa, G.P., Gray, R.N., 2008. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Int. Med. 148, 16-29. (Pubitemid 351664943)
30. Morimoto, T., Gandhi, T.K., Fiskio, J.M., Seger, A.C., So, J.W., Cook, E.F., Fukui, T., Bates, D.W., 2004. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J. Eval. Clin. Pract. 10, 499-509. (Pubitemid 39469033)
31. Mould, D.R., Upton, R.N., 2012. Basic concepts in population modeling, simulation, and model-based drug development. CPT: Pharmacometrics Syst. Pharmacol. 1 (9), e6.
32. Nchinda, A.T., Chibale, K., Redelinghuys, P., Sturrock, E.D., 2006. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. Bioorg. Med. Chem. Lett. 16, 4616-4619. (Pubitemid 44094069)
33. Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., Agostoni, A., 1998. Plasma bradykinin in angio-oedema. Lancet 351, 1693-1697. (Pubitemid 28254530)
34. Pfeffer, M.A., Frohlich, E.D., 2006. Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am. J. Physiol Heart Circ. Physiol 291, H2021-H2025.
35. Remko, M., 2007. Acidity, lipophilicity, solubility, absorption and polar surface area of some ACE inhibitors. Chem. pap. 61, 133-141.
36. Sleight, P., 2002. Angiotensin II and trials of cardiovascular outcomes. Am. J. Cardiol. 2002 (02/12), 11A-16A.
37. Song, J.C., White, C.M., 2002. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet. 41, 207-224. (Pubitemid 34415839)
38. Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G., Corvol, P., 1988. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. U.S.A. 85, 9386-9390. (Pubitemid 19027137)
39. Van de Waterbeemd, H., Smith, D., Jones, B., 2013. Lipophilicity in PK design:methyl, ethyl, futile. J. Comput. Aided Mol. Des. 15, 273-286.
40. van Vark, L.C., Bertrand, M., Akkerhuis, K.M., Brugts, J.J., Fox, K., Mourad, J.J., Boersma, E., 2012. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 33, 2088-2097.
41. Waldmeier, F., Glaenzel, U., Wirz, B., Oberer, L., Schmid, D., Seiberling, M., Valencia, J., Riviere, G.J., End, P., Vaidyanathan, S., 2007. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab. Dispos. 35, 1418-1428. (Pubitemid 47121784)
42. Watermeyer, J.M., Kroger, W.L., O'Neill, H.G., Sewell, B.T., Sturrock, E.D., 2010. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem. J. 428, 67-74.